Novel valosin-containing protein mutations associated with multisystem proteinopathy

[1]  Prashant Mishra,et al.  Valosin-containing protein (VCP/p97) inhibitors relieve Mitofusin-dependent mitochondrial defects due to VCP disease mutants , 2017, eLife.

[2]  J. Pedroso,et al.  One family, one gene and three phenotypes: A novel VCP (valosin-containing protein) mutation associated with myopathy with rimmed vacuoles, amyotrophic lateral sclerosis and frontotemporal dementia , 2016, Journal of the Neurological Sciences.

[3]  V. Kimonis,et al.  215th ENMC International Workshop VCP-related multi-system proteinopathy (IBMPFD) 13–15 November 2015, Heemskerk, The Netherlands , 2016, Neuromuscular Disorders.

[4]  Yu-ying Zhou,et al.  Frontotemporal dementia-related gene mutations in clinical dementia patients from a Chinese population , 2016, Journal of Human Genetics.

[5]  V. Cassar-Pullicino,et al.  Paget Disease of Bone , 2016, Seminars in Musculoskeletal Radiology.

[6]  Zhenlin Zhang,et al.  Pathogenic Mutations in the Valosin-containing Protein/p97(VCP) N-domain Inhibit the SUMOylation of VCP and Lead to Impaired Stress Response* , 2016, The Journal of Biological Chemistry.

[7]  C. Gilissen,et al.  Clinical exome sequencing for cerebellar ataxia and spastic paraplegia uncovers novel gene–disease associations and unanticipated rare disorders , 2016, European Journal of Human Genetics.

[8]  Y. Hsueh,et al.  VCP and ATL1 regulate endoplasmic reticulum and protein synthesis for dendritic spine formation , 2016, Nature Communications.

[9]  Christophe Béroud,et al.  UMD‐Predictor: A High‐Throughput Sequencing Compliant System for Pathogenicity Prediction of any Human cDNA Substitution , 2016, Human mutation.

[10]  K. Bushby,et al.  Mutational spectrum and phenotypic variability of VCP-related neurological disease in the UK , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[11]  R. Gibbs,et al.  Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies. , 2015, Human molecular genetics.

[12]  Michael A. Gonzalez,et al.  Rare Manifestation of a c.290 C>T, p.Gly97Glu VCP Mutation , 2015, Case reports in genetics.

[13]  J. Belleroche,et al.  VCP mutations are not a major cause of familial amyotrophic lateral sclerosis in the UK , 2015, Journal of the Neurological Sciences.

[14]  R. Youle,et al.  The Roles of PINK1, Parkin, and Mitochondrial Fidelity in Parkinson’s Disease , 2015, Neuron.

[15]  Joshua L. Deignan,et al.  Clinical exome sequencing for genetic identification of rare Mendelian disorders. , 2014, JAMA.

[16]  S. Blanton,et al.  A novel mutation in VCP causes Charcot-Marie-Tooth Type 2 disease. , 2014, Brain : a journal of neurology.

[17]  H. Meyer,et al.  The VCP/p97 system at a glance: connecting cellular function to disease pathogenesis , 2014, Journal of Cell Science.

[18]  S. Ralston,et al.  Clinical Presentation of Paget’s Disease: Evaluation of a Contemporary Cohort and Systematic Review , 2014, Calcified Tissue International.

[19]  Jana Marie Schwarz,et al.  MutationTaster2: mutation prediction for the deep-sequencing age , 2014, Nature Methods.

[20]  M. Benatar,et al.  Motor neuron involvement in multisystem proteinopathy , 2013, Neurology.

[21]  J. Platt,et al.  Genotype–phenotype studies of VCP‐associated inclusion body myopathy with Paget disease of bone and/or frontotemporal dementia , 2013, Clinical genetics.

[22]  G. Dorn,et al.  PINK1-Phosphorylated Mitofusin 2 Is a Parkin Receptor for Culling Damaged Mitochondria , 2013, Science.

[23]  L. Pallanck,et al.  VCP Is Essential for Mitochondrial Quality Control by PINK1/Parkin and this Function Is Impaired by VCP Mutations , 2013, Neuron.

[24]  S. DeKosky,et al.  Phenotypic variability in three families with valosin‐containing protein mutation , 2013, European journal of neurology.

[25]  J. Miller,et al.  Predicting the Functional Effect of Amino Acid Substitutions and Indels , 2012, PloS one.

[26]  Sonja W. Scholz,et al.  Valosin-containing protein (VCP) mutations in sporadic amyotrophic lateral sclerosis , 2012, Neurobiology of Aging.

[27]  J. Tehranzadeh,et al.  Radiological features of Paget disease of bone associated with VCP myopathy , 2012, Skeletal Radiology.

[28]  P. Freemont,et al.  The Role of the N-Domain in the ATPase Activity of the Mammalian AAA ATPase p97/VCP , 2012, The Journal of Biological Chemistry.

[29]  T. Saigusa,et al.  Mitophagy Plays an Essential Role in Reducing Mitochondrial Production of Reactive Oxygen Species and Mutation of Mitochondrial DNA by Maintaining Mitochondrial Quantity and Quality in Yeast* , 2011, The Journal of Biological Chemistry.

[30]  Charles D. Smith,et al.  The Multiple Faces of Valosin-Containing Protein-Associated Diseases: Inclusion Body Myopathy with Paget’s Disease of Bone, Frontotemporal Dementia, and Amyotrophic Lateral Sclerosis , 2011, Journal of Molecular Neuroscience.

[31]  H. Haapasalo,et al.  Distinct distal myopathy phenotype caused by VCP gene mutation in a Finnish family , 2011, Neuromuscular Disorders.

[32]  R. Youle,et al.  Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by Parkin , 2010, The Journal of cell biology.

[33]  Sonja W. Scholz,et al.  Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS , 2010, Neuron.

[34]  S. Ellard,et al.  Using SIFT and PolyPhen to predict loss-of-function and gain-of-function mutations. , 2010, Genetic testing and molecular biomarkers.

[35]  A. Buchberger,et al.  Imbalances in p97 co‐factor interactions in human proteinopathy , 2010, EMBO reports.

[36]  D. Cleveland,et al.  TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. , 2010, Human molecular genetics.

[37]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[38]  M. Latterich,et al.  Hereditary Inclusion Body Myopathy-Linked p97/VCP Mutations in the NH2 Domain and the D1 Ring Modulate p97/VCP ATPase Activity and D2 Ring Conformation , 2009, Molecular and Cellular Biology.

[39]  K. Claeys,et al.  Clinical outcome in 19 French and Spanish patients with valosin-containing protein myopathy associated with Paget’s disease of bone and frontotemporal dementia , 2009, Neuromuscular Disorders.

[40]  C. Smart,et al.  Inclusion body myopathy with Paget disease and frontotemporal dementia (IBMPFD): clinical features including sphincter disturbance in a large pedigree , 2009, Journal of Neurology, Neurosurgery, and Psychiatry.

[41]  A. Pestronk,et al.  TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[42]  A. Buchberger,et al.  UBX domain proteins: major regulators of the AAA ATPase Cdc48/p97 , 2008, Cellular and Molecular Life Sciences.

[43]  Charles D. Smith,et al.  Clinical studies in familial VCP myopathy associated with Paget disease of bone and frontotemporal dementia , 2008, American journal of medical genetics. Part A.

[44]  R. Isaacson,et al.  Insights into adaptor binding to the AAA protein p97. , 2008, Biochemical Society transactions.

[45]  D. Drachman,et al.  Novel VCP mutations in inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia , 2007, Clinical genetics.

[46]  J. Morris,et al.  TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. , 2007, The American journal of pathology.

[47]  N. Cairns,et al.  TDP‐43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations , 2007, Journal of neuropathology and experimental neurology.

[48]  C. Duyckaerts,et al.  Valosin-containing protein gene mutations , 2006, Neurology.

[49]  Charles D. Smith,et al.  Novel Ubiquitin Neuropathology in Frontotemporal Dementia With Valosin-Containing Protein Gene Mutations , 2006, Journal of neuropathology and experimental neurology.

[50]  C. van Broeckhoven,et al.  Characterization of Ubiquitinated Intraneuronal Inclusions in a Novel Belgian Frontotemporal Lobar Degeneration Family , 2006, Journal of neuropathology and experimental neurology.

[51]  F. Zimprich,et al.  Inclusion body myopathy and Paget disease is linked to a novel mutation in the VCP gene , 2005, Neurology.

[52]  H. Kondo,et al.  p97/p47-Mediated biogenesis of Golgi and ER. , 2005, Journal of biochemistry.

[53]  A. Pestronk,et al.  Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein , 2004, Nature Genetics.

[54]  Yixian Zheng,et al.  The AAA-ATPase Cdc48/p97 Regulates Spindle Disassembly at the End of Mitosis , 2003, Cell.

[55]  K. Okamoto,et al.  Vacuole-creating protein in neurodegenerative diseases in humans , 2003, Neuroscience Letters.

[56]  Chou-Chi H. Li,et al.  Hexamerization of p97-VCP is promoted by ATP binding to the D1 domain and required for ATPase and biological activities. , 2003, Biochemical and biophysical research communications.

[57]  K. Fröhlich,et al.  AAA-ATPase p97/Cdc48p, a Cytosolic Chaperone Required for Endoplasmic Reticulum-Associated Protein Degradation , 2002, Molecular and Cellular Biology.

[58]  M. Hetzer,et al.  Distinct AAA-ATPase p97 complexes function in discrete steps of nuclear assembly , 2001, Nature Cell Biology.

[59]  S. Jentsch,et al.  Mobilization of Processed, Membrane-Tethered SPT23 Transcription Factor by CDC48UFD1/NPL4, a Ubiquitin-Selective Chaperone , 2001, Cell.

[60]  S. Leal,et al.  Clinical and molecular studies in a unique family with autosomal dominant limb-girdle muscular dystrophy and Paget disease of bone , 2000, Genetics in Medicine.

[61]  J. Newman,et al.  Complications in Paget disease at MR imaging. , 1998, Radiology.

[62]  Hisao Kondo,et al.  Syntaxin 5 Is a Common Component of the NSF- and p97-Mediated Reassembly Pathways of Golgi Cisternae from Mitotic Golgi Fragments In Vitro , 1998, Cell.

[63]  D. Botstein,et al.  Yeast cell cycle protein CDC48p shows full-length homology to the mammalian protein VCP and is a member of a protein family involved in secretion, peroxisome formation, and gene expression , 1991, The Journal of cell biology.

[64]  V. Mutt,et al.  Valosin: isolation and characterization of a novel peptide from porcine intestine , 1985, FEBS letters.

[65]  J. Bronstein,et al.  Valosin-containing protein mutation and Parkinson's disease. , 2012, Parkinsonism & related disorders.

[66]  S. Henikoff,et al.  Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.

[67]  E. Buratti,et al.  Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease. , 2008, Frontiers in bioscience : a journal and virtual library.

[68]  Charles D. Smith,et al.  APOE is a potential modifier gene in an autosomal dominant form of frontotemporal dementia (IBMPFD) , 2007, Genetics in Medicine.